NCT07282587Phase 2Recruiting

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-12-15Estimated

Enrollment · participants90Estimated

Source updated2026-06-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-27 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Advanced Pheochromocytoma and Paraganglioma; PCPG

Treatments or interventions studied

ONC206Drug
ONC206: Dose 1Drug
ONC206: Dose 2Drug

Primary outcomes · main study measures

measure: Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; description: ORR defined as the number of participants with a confirmed complete response (CR) or partial response during the study, as per RECIST v1.1.; timeFrame: Up to 36 months.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history